Article

Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial.

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Electronic address: .
The Lancet (Impact Factor: 39.21). 11/2012; 380(9857). DOI: 10.1016/S0140-6736(12)61380-4
Source: PubMed

ABSTRACT BACKGROUND: Catheter-associated urinary tract infection (CAUTI) is a major preventable cause of harm for patients in hospital. We aimed to establish whether short-term routine use of antimicrobial catheters reduced risk of CAUTI compared with standard polytetrafluoroethylene (PTFE) catheterisation. METHODS: In our parallel, three group, multicentre, randomised controlled superiority trial, we enrolled adults (aged ≥16 years) requiring short-term (≤14 days) catheterisation at 24 hospitals in the UK. Participants were randomly allocated 1:1:1 with a remote computer allocation to receive a silver alloy-coated catheter, a nitrofural-impregnated catheter, or a PTFE-coated catheter (control group). Patients undergoing unplanned catheterisation were also included and consent for participation was obtained retrospectively. Participants and trial staff were unmasked to treatment assignment. Data were collected by trial staff and by patient-reported questionnaires for 6 weeks after randomisation. The primary outcome was incidence of symptomatic urinary tract infection for which an antibiotic was prescribed by 6 weeks. We postulated that a 3·3% absolute reduction in CAUTI would represent sufficient benefit to recommend routine use of antimicrobial catheters. This study is registered, number ISRCTN75198618. FINDINGS: 708 (10%) of 7102 randomly allocated participants were not catheterised, did not confirm consent, or withdrew, and were not included in the primary analyses. Compared with 271 (12·6%) of 2144 participants in the control group, 263 (12·5%) of 2097 participants allocated a silver alloy catheter had the primary outcome (difference -0·1% [95% CI -2·4 to 2·2]), as did 228 (10·6%) of 2153 participants allocated a nitrofural catheter (-2·1% [-4·2 to 0·1]). Rates of catheter-related discomfort were higher in the nitrofural group than they were in the other groups. INTERPRETATION: Silver alloy-coated catheters were not effective for reduction of incidence of symptomatic CAUTI. The reduction we noted in CAUTI associated with nitrofural-impregnated catheters was less than that regarded as clinically important. Routine use of antimicrobial-impregnated catheters is not supported by this trial. FUNDING: UK National Institute for Health Research Health Technology Assessment Programme.

0 Bookmarks
 · 
105 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This article highlights the authors' experience in the management of facial asymmetries with the use of distraction osteogenesis. It is a narrative based on the clinical experience at the Meenakshi Cleft & Craniofacial Center at Chennai.
    Journal of Craniofacial Surgery 09/2014; 25(5):1665-1667. · 0.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Microorganisms from a patient or their environment may colonize indwelling urinary catheters, forming biofilm communities on catheter surfaces and increasing patient morbidity and mortality. This study investigated the effect of pre-treating hydrogel-coated silicone catheters with mixtures of Pseudomonas aeruginosa and Proteus mirabilis bacteriophages on the development of single- and two-species biofilms in a multi-day, continuous-flow in vitro model using artificial urine. Novel phages were purified from sewage, characterized, and screened for their ability to reduce biofilm development by clinical isolates of their respective hosts. Screening data showed that Artificial Urine Medium (AUM) is a valid substitute for human urine for the purpose of evaluating uropathogen biofilm control by these bacteriophages. Defined phage cocktails targeting each of P. aeruginosa and P. mirabilis were designed based on biofilm inhibition screens. Hydrogel-coated catheters were pre-treated with one or both cocktails and challenged with approximately 1×10(3) CFU/mL of the corresponding pathogen(s). Biofilm growth on catheter surfaces in AUM was monitored over 72 to 96 h. Phage pre-treatment reduced P. aeruginosa biofilm counts by 4 log10CFU/cm(2) (p≤0.01) and P. mirabilis biofilm counts by > 2 log10 CFU/cm(2) (p ≤0.01) over 48 h. The presence of P. mirabilis was always associated with an increase in lumen pH from 7.5 to 9.5, and with eventual blockage of the reactor lines. Results of this study suggest that pretreatment of a hydrogel urinary catheter with a phage cocktail can significantly reduce mixed species biofilm formation by clinically relevant bacteria. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 12/2014; · 4.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biofilms are colonies of bacteria or fungi that adhere to a surface, protected by an extracellular polymer matrix composed of polysaccharides and extracellular DNA. They are highly complex and dynamic multicellular structures that resist traditional means of killing planktonic bacteria. Recent developments in nanotechnology provide novel approaches to preventing and dispersing biofilm infections, which are a leading cause of morbidity and mortality. Medical device infections are responsible for approximately 60% of hospital acquired infections. In the United States, the estimated cost of caring for healthcare-associated infections is approximately between $28 billion and $45 billion per year. In this review, we will discuss our current understanding of biofilm formation and degradation, its relevance to challenges in clinical practice, and new technological developments in nanotechnology that are designed to address these challenges.
    Journal of Biomedical Nanotechnology 10/2014; 10(10):2806-2827. · 7.58 Impact Factor

Full-text (3 Sources)

Download
53 Downloads
Available from
Jun 2, 2014